Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights

Rhea-AI Summary

Hemogenyx Pharmaceuticals plc (OTC PINK:HOPHF) announced on March 31, 2021, that its total issued share capital comprises 454,509,503 ordinary shares of 1 pence each, with none held in treasury. This total establishes the number of voting rights available to shareholders, which they may use as a denominator for notifications regarding changes in their investment under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. The company emphasizes that all shares are fully issued and voting rights are in effect.

Positive

• Total issued share capital is 454,509,503 ordinary shares, providing clear shareholder representation.
• No treasury shares indicate all shares are available for shareholder voting.

Negative

• None.

LONDON, UK / ACCESSWIRE / March 31, 2021 / Hemogenyx Pharmaceuticals plc (OTC PINK:HOPHF)(LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 31 March 2021 consists of 454,509,503 ordinary shares of 1 pence each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 454,509,503.

The figure of 454,509,503 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Enquiries:
Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	headquarters@hemogenyx.com
Peter Redmond, Director	peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View source version on accesswire.com:
https://www.accesswire.com/638295/Hemogenyx-Pharmaceuticals-PLC-Announces-Total-Voting-Rights

FAQ

What is the total number of shares for Hemogenyx Pharmaceuticals as of March 31, 2021?

As of March 31, 2021, Hemogenyx Pharmaceuticals has a total of 454,509,503 ordinary shares issued.

What does the total issued share capital mean for Hemogenyx Pharmaceuticals?

The total issued share capital refers to the total number of shares available for voting by shareholders, which is 454,509,503.

How does the share capital affect voting rights in Hemogenyx Pharmaceuticals?

The total issued share capital serves as the denominator for shareholders to calculate if they need to inform changes in their investment according to regulations.